Creative Bioarray launches hERG safety assay service to enhance drug development safety by detecting cardiotoxicity early. Learn how this innovation benefits researchersCreative Bioarray launches hERG safety assay service to enhance drug development safety by detecting cardiotoxicity early. Learn how this innovation benefits researchers

Creative Bioarray Launches Comprehensive hERG Safety Assay Service to Enhance Drug Development

2026/01/31 16:00
2 min di lettura
Per feedback o dubbi su questo contenuto, contattateci all'indirizzo crypto.news@mexc.com.

Creative Bioarray has announced the launch of its flagship hERG safety assay service, aimed at enhancing drug development by identifying potential cardiotoxic risks in compounds during early research stages. The service addresses a critical pharmaceutical industry challenge where blockage of hERG potassium channels can lead to life-threatening cardiac side effects, making safety assessment paramount for new therapies.

The company utilizes advanced assay methods to assess potential cardiotoxicity of drug candidates, optimizing traditional screening approaches with modern technologies to deliver high-throughput, reliable results. According to Hannah Cole, a spokesperson for Creative Bioarray, the service provides a vital tool for pharmaceutical companies and researchers looking to streamline their drug development process by offering critical information needed to make informed decisions about compound safety.

Creative Bioarray’s hERG safety assay can be integrated into early drug development stages, potentially improving project efficiency and helping bring safer drugs to market faster. The company provides clients with detailed data interpretations to help scientists optimize lead compounds while reducing the risk of late-stage development failure due to cardiotoxicity. The service is designed to benefit a wide range of pharmaceutical industry stakeholders, including biotechnology companies, contract research organizations, and academic institutions.

The company has cultivated a team of experienced experts with extensive expertise in pharmacology, electrophysiology, and drug safety assessment, offering not only accurate assays but also comprehensive analysis and guidance throughout the research process. In addition to hERG safety testing, Creative Bioarray offers a range of other bioassays, customized services, and products to meet specific research needs. More information about their services can be found at https://www.creative-bioarray.com.

Blockchain Registration, Verification & Enhancement provided by NewsRamp™

This news story relied on content distributed by 24-7 Press Release. Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is Creative Bioarray Launches Comprehensive hERG Safety Assay Service to Enhance Drug Development.

The post Creative Bioarray Launches Comprehensive hERG Safety Assay Service to Enhance Drug Development appeared first on citybuzz.

Disclaimer: gli articoli ripubblicati su questo sito provengono da piattaforme pubbliche e sono forniti esclusivamente a scopo informativo. Non riflettono necessariamente le opinioni di MEXC. Tutti i diritti rimangono agli autori originali. Se ritieni che un contenuto violi i diritti di terze parti, contatta crypto.news@mexc.com per la rimozione. MEXC non fornisce alcuna garanzia in merito all'accuratezza, completezza o tempestività del contenuto e non è responsabile per eventuali azioni intraprese sulla base delle informazioni fornite. Il contenuto non costituisce consulenza finanziaria, legale o professionale di altro tipo, né deve essere considerato una raccomandazione o un'approvazione da parte di MEXC.

Trading GOLD per 1,000,000 USDT

Trading GOLD per 1,000,000 USDTTrading GOLD per 1,000,000 USDT

0 commissioni, leva fino 1,000x, liquidità profonda